Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Hull Royal Infirmary

Hull, HU3 2JZ, United KingdomNot linked to an institution yet

30running trials
9closed trials

The trials here

What the 39 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes11 trials
Obesity10 trials
Fatty liver disease (MASLD/MASH)5 trials
Stroke4 trials
Coronary artery disease3 trials
Liver cirrhosis3 trials
Macular degeneration3 trials
Chronic kidney disease2 trials
Diabetic eye disease2 trials
Peripheral artery disease2 trials
Primary biliary cholangitis2 trials
Aortic aneurysm1 trial
and 12 more
Phase: Phase 328 trials
Phase 11 trial
Phase 21 trial
Phase 41 trial
Status: Recruiting15 trials
Active, not recruiting14 trials
Completed9 trials
Enrolling by invitation1 trial
Lead sponsor: Eli Lilly and Company8 trials
Amgen4 trials
Novo Nordisk A/S4 trials
Boehringer Ingelheim3 trials
Hoffmann-La Roche3 trials
and 16 more

Running trials

Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· Phase 3· Eli Lilly and Company· Source
Contact: Sanjay Gupta (principal investigator)
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546· Phase 3· Rhythm Pharmaceuticals, Inc.· Source
Contact: Rhythm Clinical Trials
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
NCT06985706· Phase 3· Belfast Health and Social Care Trust· Source
Contact: Mary Guiney
Enrolling by invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07055607· Novo Nordisk A/S· Source
Active, not recruiting
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· Phase 3· Amgen· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939· Phase 3· Eli Lilly and Company· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464· Phase 3· Harmony Biosciences Management, Inc.· Source
Contact: Thozhukat Sathyapalan, MBBS, MD
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· Phase 3· Gilead Sciences· Source
Active, not recruiting
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
NCT05944432· Abbott Diabetes Care· Source
Recruiting
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
NCT06461208· Phase 3· King's College London· Source
Contact: Lynsey Corless
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584· Phase 4· Eli Lilly and Company· Source
Recruiting
Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
NCT04936620· St George's, University of London· Source
Contact: Vasileios Arzoglou (principal investigator)
Recruiting
Endoscopic Severity Image Recognition to Advance Research and Training in Inflammatory Bowel Disease (EVEREST - IBD)
NCT04867408· Hull University Teaching Hospitals NHS Trust· Source
Contact: Shaji Sebastian
Active, not recruiting
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source
Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· Phase 3· Population Health Research Institute· Source
Contact: Ian Chetter
Recruiting
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT04663750· Phase 3· King's College Hospital NHS Trust· Source
Contact: Abdallah Ellabban (principal investigator)
Active, not recruiting
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181· Phase 3· Novo Nordisk A/S· Source
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463· Vascutek Ltd.· Source
Contact: Raghuram Lakshminarayan, DR (principal investigator)
Active, not recruiting
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506· Phase 3· Gilead Sciences· Source
Recruiting
The European NAFLD Registry
NCT04442334· Newcastle University· Source
Contact: Lynsey Corless, MBChB, PhD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
NCT05848258· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
NCT05174221· Phase 1· Takeda· Source
Completed
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
NCT05260021· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110· Phase 3· Boehringer Ingelheim· Source
Completed
Multiple Sclerosis-Simvastatin Trial 2
NCT03387670· Phase 3· University College, London· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error

Under construction, not live – Hull Royal Infirmary: trial site – Frontlight Research